DOCSLIB.ORG

Acquired Hemolytic Anemia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Acquired Hemolytic Anemia 24. Neave L, Scully M: Microangiopathic hemolytic anemia in pregnancy. Transfus Med Rev CHAPTER Acquired Hemolytic 32: 230, 2018. [PMID: 30177429] 25. Brecher ME, Hay SN, Park YA: Is it HIV TTP or HIV-associated thrombotic microangi- Anemia opathy? J Clin Apher 23: 186, 2008. [PMID: 18973113] 237 26. Dias PJ, Gopal S: Refractory thrombotic thrombocytopenic purpura following influenza Laurie Ann Dixon vaccination. Anaesthesia 64: 444, 2009. [PMID: 19317713] 27. Piton G, Navellou JC, Morati P, et al: Thrombotic thrombocytopenic purpura associated Robin R. Hemphill with severe acute pancreatitis in a context of decreased ADAMTS13 activity: a case report. Eur J Gastroenterol Hepatol 12: 1226, 2008. [PMID: 18989146] 28. McDonald V, Laffan M, Benjamin S, et al: Thrombotic thrombocytopenic purpura pre- REFERENCES cipitated by acute pancreatitis: a report of seven cases from a regional UK TTP registry. Br J Haematol 3: 430, 2008. [PMID: 19036107] 1. Bass GF, Tuscano ET, Tuscano JM: Diagnosis and classification of autoimmune hemo- 29. Zakarija A, Kwaan HC, Moake JL, et al: Ticlopidine- and clopidogrel-associated throm- lytic anemia. Autoimmun Rev 13: 560, 2014. [PMID: 24418298] botic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, 2. Liebman HA, Weitz IC: Autoimmune hemolytic anemia. Med Clin North Am 101: 351, and pharmacovigilance findings (1989-2000). Kidney Int Suppl 112: S20, 2009. [PMID: 2017. [PMID: 28189175] 19180126] 3. Michel M: Warm autoimmune hemolytic anemia: advances in pathophysiology and 30. Wada H, Matsumoto T, Suzuki K, et al: Differences and similarities between dissemi- treatment. Presse Med 43 (4 Pt 2): e97, 2014. [PMID: 24680421] nated intravascular coagulation and thrombotic microangiopathy. Thromb J 16: 14, 2018. 4. Kalfa TA: Warm antibody autoimmune hemolytic anemia. Hematology Am Soc Hematol [PMID: 30008620] Educ Program 2016: 690, 2016. [PMID: 27913548] 31. Alvarez-Larran A, Del Rio G, Pujol M, et al: Newly diagnosed versus relapsed idiopathic 5. Taniguchi LU, Correia MD, Zampieri FG: Overwhelming postsplenectomy infection: thrombotic thrombocytopenic purpura: a comparison of presenting clinical characteris- narrative review of the literature. Surg Infect (Larchmt) 15: 686, 2014. [PMID: 25318011] tics and response to treatment. Ann Hematol 88: 973, 2009. [PMID: 19205654] 6. Theilacker C, Ludewig K, Serr A, et al: Overwhelming postsplenectomy infection: a 32. Salvadori M, Bertoni E: Update on hemolytic uremic syndrome: diagnostic and thera- prospective multicenter cohort study. Clin Infect Dis 62: 871, 2016. [PMID: 26703862] peutic recommendations. World J Nephrol 2: 56, 2013. [PMID: 24255888] 7. Sinwar PD: Overwhelming post splenectomy infection syndrome: review study. Int J Surg 33. Keithlin J, Sargeant J, Thomas MK, Fazil A: Chronic sequelae of E. coli O157: systematic 12: 1314, 2014. [PMID: 25463041] review and meta-analysis of the proportion of E. coli O157 cases that develop chronic 8. Drouillard D: Transfusion therapy for autoimmune hemolytic anemia patients: a labora- sequelae. Foodborne Pathog Dis 11: 79, 2014. [PMID: 24404780] tory perspective. Clin Lab Sci 21: 7, 2008. [PMID: 18335854] 34. Rock GA, Clark WF: Mechanism of microthrombosis in HUS. Kidney Int Suppl 112: S15, 9. Quist E, Koepsell S: Autoimmune hemolytic anemia and red blood cell autoantibodies. 2009. [PMID: 19180124] Arch Pathol Lab Med 139: 1455, 2015. [PMID: 26516943] 35. Suri RS: Relationship between Escherichia coli O157:H7 and diabetes mellitus. Kidney Int 10. Chaudhary RK. Das SS: Autoimmune hemolytic anemia: from lab to bedside. Asian J Suppl 112: S44, 2009. [PMID: 19180134] Transfus Sci 8: 5, 2014. [PMID: 24678166] 36. Grisaru S: Management of hemolytic-uremic syndrome in children. Int J Nephrol Ren 11. Swiecicki PL, Hegerova LT, Gertz MA: Cold agglutinin disease. Blood 122: 1114, 2013. vasc Dis 7: 231, 2014. [PMID: 24966691] [PMID: 23757733] 37. Davis TK, Van De Kar NC, Tarr PI: Shiga toxin/verocytotoxin-producing Escherichia coli 12. Jeskowiak A, Goerge T: Images in clinical medicine. Cutaneous necrosis associated with infections: practical clinical perspectives. Microbiol Spectr 2: EHEC-0025-2014, 2014. cold agglutinins. N Engl J Med 369: e1, 2013. [PMID: 23822796] [PMID: 26104210] 13. Kauke T, Reininger AJ: Images in clinical medicine. Livedo reticularis and cold aggluti- 38. Karmali MA: Host and pathogen determinants of verocytotoxin-producing Escherichia nins. N Engl J Med 356: 284, 2007. [PMID: 17229955] coli-associated hemolytic uremic syndrome. Kidney Int Suppl 112: S4, 2009. [PMID: 14. Berentsen S: Cold agglutinin disease. Hematology Am Soc Hematol Educ Program 1: 226, 19180132] 2016. [PMID: 27913484] 39. Kaplan BS, Ruebner RL, Spinale JM, Copelovitch L: Current treatment of atypical hemo- 15. Slemp SN, Davisson SM, Slayten J, Cipkala DA, Waxman DA: Two case studies and a lytic uremic syndrome. Intractable Rare Dis Res 3: 34, 2014. [PMID: 25343125] review of paroxysmal cold hemoglobinuria. Lab Med 45: 253, 2014. [PMID: 25051079] 40. Shapira Y, Vaturi M, Sagie A: Hemolysis associated with prosthetic heart valves: a review. 16. Moise KJ: Hemolytic disease of the fetus and newborn. Clin Adv Hematol Oncol 11: 664, Cardiol Rev 17: 121, 2009. [PMID: 19384085] 2013. [PMID: 24518377] 41. Heilmann C, Geisen U, Benk C, et al: Haemolysis in patients with ventricular assist 17. Arndt PA: Drug-induced immune hemolytic anemia: the last 30 years of changes. Immu- devices: major differences between systems. Eur J Cardiothorac Surg 36: 580. 2009. nohematology 30: 44, 2014. [PMID: 25247622] [PMID: 19464915] 18. Garratty G, Arndt PA: Drugs that have been shown to cause drug-induced immune 42. Tharmaraj D, Kerr P: Haemolysis in haemodialysis. Nephrology (Carlton) 22: 838, 2017. hemolytic anemia or positive direct antiglobulin tests: some interesting findings since [PMID: 28749067] 2007. Immunohematology 30: 66, 2014. [PMID: 25247621] 43. Song Y, Wang D, Li H, et al: Severe acute arsine poisoning treated by plasma exchange. 19. George JN, Nester CM: Syndromes of thrombotic microangiopathy. N Engl J Med 371: Clin Toxicol 45: 72, 2007. [PMID: 17849251] 654, 2014. [PMID: 25119611] 44. Pullen-James S, Woods SE: Occupational arsine gas exposure. J Natl Med Assoc 98: 1998, 20. Kappler S, Ronan-Bentle S, Graham A: Thrombotic microangiopathies (TTP, HUS, 2006. [PMID: 17225850] HELLP). Hematol Oncol Clin North Am 31: 1081, 2017. [PMID: 29078925] 45. Vasudev M, Bresnahan BA, Cohen EP, Hari PN, Hariharan S, Vasudev BS: Percussion 21. Scully M: Trends in the diagnosis and management of TTP: European perspective. Trans- hemoglobinuria: a novel term for hand trauma-induced mechanical hemolysis: a case fus Apher Sci 51: 11, 2014. [PMID: 25305101] report. J Med Case Rep 5: 508, 2011. [PMID: 21982397] 22. George JN: The thrombotic thrombocytopenic purpura and hemolytic uremic syn- 46. Siomou E, Baziou M, Premetis E, Vercellati C, Chaliasos N, Makis A: Repetitive reddish dromes: evaluation, management, and long-term outcomes experience of the Oklahoma discoloration of urine in a female adolescent following short-distance walking on a TTP-HUS registry, 1989–2007. Kidney Int Suppl 112: S52, 2009. [PMID: 19180137] smooth road: questions. Pediatr Nephrol 32: 2253, 2017. [PMID: 28194571] 23. Tsai HM: Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic 47. Siomou E, Baziou M, Premetis E, Vercellati C, Chaliasos N, Makis A: Repetitive reddish purpura. Kidney Int Suppl 112: S11, 2009. [PMID: 19180123] discoloration of the urine in an adolescent female following short-distance walking on a smooth road: answers. Pediatr Nephrol 32: 2255, 2017. [PMID: 28194572] 1 Tintinalli_Ch237_References.indd 1 24/07/19 5:06 PM.
Load more

Recommended publications
  • Acoi Board Review 2019 Text
    CHERYL KOVALSKI, DO FACOI NO DISCLOSURES ACOI BOARD REVIEW 2019 TEXT ANEMIA ‣ Hemoglobin <13 grams or ‣ Hematocrit<39% TEXT ANEMIA MCV RETICULOCYTE COUNT Corrected retic ct = hematocrit/45 x retic % (45 considered normal hematocrit) >2%: blood loss or hemolysis <2%: hypoproliferative process TEXT ANEMIA ‣ MICROCYTIC ‣ Obtain and interpret iron studies ‣ Serum iron ‣ Total iron binding capacity (TIBC) ‣ Transferrin saturation ‣ Ferritin-correlates with total iron stores ‣ can be normal or increased if co-existent inflammation TEXT IRON DEFICIENCY ‣ Most common nutritional problem in the world ‣ Absorbed in small bowel, enhanced by gastric acid ‣ Absorption inhibited by inflammation, phytates (bran) & tannins (tea) TEXT CAUSES OF IRON DEFICIENCY ‣ Blood loss – most common etiology ‣ Decreased intake ‣ Increased utilization-EPO therapy, chronic hemolysis ‣ Malabsorption – gastrectomy, sprue ‣ ‣ ‣ TEXT CLINICAL MANIFESTATIONS OF IRON DEFICIENCY ‣ Impaired psychomotor development ‣ Fatigue, Irritability ‣ PICA ‣ Koilonychiae, Glossitis, Angular stomatitis ‣ Dysphagia TEXT IRON DEFICIENCY LAB FINDINGS ‣ Low serum iron, increased TIBC ‣ % sat <20 TEXT MANAGEMENT OF IRON DEFICIENCY ‣ MUST LOOK FOR SOURCE OF BLEED: ie: GI, GU, Regular blood donor ‣ Replacement: 1. Oral: Ferrous sulfate 325 mg TID until serum iron, % sat, and ferritin mid-range normal, 6-12 months 2. IV TEXT SIDEROBLASTIC ANEMIAS Diverse group of disorders of RBC production characterized by: 1. Defect involving incorporation of iron into heme molecule 2. Ringed sideroblasts in
    [Show full text]
  • Approach to Anemia
    APPROACH TO ANEMIA Mahsa Mohebtash, MD Medstar Union Memorial Hospital Definition of Anemia • Reduced red blood mass • RBC measurements: RBC mass, Hgb, Hct or RBC count • Hgb, Hct and RBC count typically decrease in parallel except in severe microcytosis (like thalassemia) Normal Range of Hgb/Hct • NL range: many different values: • 2 SD below mean: < Hgb13.5 or Hct 41 in men and Hgb 12 or Hct of 36 in women • WHO: Hgb: <13 in men, <12 in women • Revised WHO/NCI: Hgb <14 in men, <12 in women • Scrpps-Kaiser based on race and age: based on 5th percentiles of the population in question • African-Americans: Hgb 0.5-1 lower than Caucasians Approach to Anemia • Setting: • Acute vs chronic • Isolated vs combined with leukopenia/thrombocytopenia • Pathophysiologic approach • Morphologic approach Reticulocytes • Reticulocytes life span: 3 days in bone marrow and 1 day in peripheral blood • Mature RBC life span: 110-120 days • 1% of RBCs are removed from circulation each day • Reticulocyte production index (RPI): Reticulocytes (percent) x (HCT ÷ 45) x (1 ÷ RMT): • <2 low Pathophysiologic approach • Decreased RBC production • Reduced effective production of red cells: low retic production index • Destruction of red cell precursors in marrow (ineffective erythropoiesis) • Increased RBC destruction • Blood loss Reduced RBC precursors • Low retic production index • Lack of nutrients (B12, Fe) • Bone marrow disorder => reduced RBC precursors (aplastic anemia, pure RBC aplasia, marrow infiltration) • Bone marrow suppression (drugs, chemotherapy, radiation)
    [Show full text]
  • Paroxysmal Cold Hemoglobinuria: a Case Report
    CASE R EPO R T Paroxysmal cold hemoglobinuria: a case report S.C. Wise, S.H. Tinsley, and L.O. Cook A 15-month-old white male child was admitted to the pediatric hemolysis and possible pigment nephropathy and to rule out intensive care unit with symptoms of upper respiratory tract sepsis. He was started on oxygen by nasal cannula and given infection, increased somnolence, pallor, jaundice, fever, and intravenous fluids at half maintenance rates with bicarbonate decreased activity level. The purpose of this case study is to report the clinical findings associated with the patient’s administered to alkalinize the urine to prevent crystallization clinical symptoms and differential laboratory diagnosis. of myoglobin or hemoglobin. His urine output was monitored, Immunohematology 2012;28:118–23. and fluids were given judiciously to prevent congestive heart failure. He was also started empirically on ceftriaxone. Blood Key Words: cold agglutinin syndrome (CAS), direct and urine cultures were obtained and blood samples were antiglobulin test (DAT), Donath-Landsteiner (D-L), hemolytic sent to the blood bank for compatibility testing owing to the anemia (HA), LISS (low-ionic-strength saline), indirect patient’s low hemoglobin level and symptomatic anemia. antiglobulin test (IAT), paroxysmal cold hemoglobinuria (PCH) Results Case Report Blood bank serologic test results demonstrated the patient to be group O, D+. Results of antibody screening identified A 15-month-old white male child was admitted to the reactivity only after incubation at 37°C with low-ionic-strength pediatric intensive care unit with a several-day history of upper saline (LISS). Six units were crossmatched, and all were found respiratory tract infection symptoms, followed by increased to be incompatible after incubation at 37°C with LISS.
    [Show full text]
  • Efficacy of Recombinant Erythropoietin in Autoimmune Hemolytic Anemia: a Multicenter Associated Lymphoid Cells
    Letters to the Editor CAD patients who showed typical monoclonal CAD- Efficacy of recombinant erythropoietin in autoimmune hemolytic anemia: a multicenter associated lymphoid cells. The median endogenous EPO international study was 32 U/L (9.3-1,328) greater than the normal range, but inadequate in 88% of AIHA subjects considering Hb Autoimmune hemolytic anemia (AIHA) is due to levels. Renal function was normal in all patients but two autoantibody mediated hemolysis with or without com- plement (C) activation.1,2 Increasing attention has been paid to the role of bone marrow compensation,3,4 since Table 1. Patients' characteristics at diagnosis. inadequate reticulocytosis is observed in 20-40% of cases Data at diagnosis All patients (N=51) and correlates with poor prognosis.3,5 Moreover, features resembling bone marrow failure syndromes have been Age years, median(range) 68 (25-92) described in patients with chronic and relapsed/refracto- M/F 24/27 ry AIHA, including dyserythropoiesis and fibrosis.6,7 Secondary AIHA, N(%) 5 (9) Recombinant erythropoietin (rEPO) is an established Type of AIHA treatment of myelodysplastic syndromes, which has been used in a limited number of AIHA cases.8,9 CAD, N(%) 21 (41) In this study, we systematically evaluated the safety WAIHA IgG, N(%) 11 (22) and efficacy of EPO treatment in a multicenter, interna- WAIHA IgG+C, N(%) 15 (29) tional European cohort of AIHA patients. The protocol MIXED, N(%) 3 (6) was approved by the Ethics Committees of Human Experimentation, and patients gave informed consent in DAT neg, N(%) 1 (2) accordance with the Declaration of Helsinki.
    [Show full text]
  • Download the Presentation (PDF 2.2
    Novartis Investor Relations Iptacopan (LNP023) update Investor presentation June 22, 2021 Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “expected,” “will,” “planned,” “pipeline,” “outlook,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for iptacopan or regarding potential future revenues from such product. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that iptacopan will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that iptacopan will be commercially successful in the future. In particular, our expectations regarding iptacopan could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government
    [Show full text]
  • Autoimmune Hemolytic Anemia
    Michalak et al. Immunity & Ageing (2020) 17:38 https://doi.org/10.1186/s12979-020-00208-7 REVIEW Open Access Autoimmune hemolytic anemia: current knowledge and perspectives Sylwia Sulimiera Michalak1* , Anna Olewicz-Gawlik2,3,4, Joanna Rupa-Matysek5, Edyta Wolny-Rokicka6, Elżbieta Nowakowska1 and Lidia Gil5 Abstract Autoimmune hemolytic anemia (AIHA) is an acquired, heterogeneous group of diseases which includes warm AIHA, cold agglutinin disease (CAD), mixed AIHA, paroxysmal cold hemoglobinuria and atypical AIHA. Currently CAD is defined as a chronic, clonal lymphoproliferative disorder, while the presence of cold agglutinins underlying other diseases is known as cold agglutinin syndrome. AIHA is mediated by autoantibodies directed against red blood cells (RBCs) causing premature erythrocyte destruction. The pathogenesis of AIHA is complex and still not fully understood. Recent studies indicate the involvement of T and B cell dysregulation, reduced CD4+ and CD25+ Tregs, increased clonal expansions of CD8 + T cells, imbalance of Th17/Tregs and Tfh/Tfr, and impaired lymphocyte apoptosis. Changes in some RBC membrane structures, under the influence of mechanical stimuli or oxidative stress, may promote autohemolysis. The clinical presentation and treatment of AIHA are influenced by many factors, including the type of AIHA, degree of hemolysis, underlying diseases, presence of concomitant comorbidities, bone marrow compensatory abilities and the presence of fibrosis and dyserthropoiesis. The main treatment for AIHA is based on the inhibition of autoantibody production by mono- or combination therapy using GKS and/or rituximab and, rarely, immunosuppressive drugs or immunomodulators. Reduction of erythrocyte destruction via splenectomy is currently the third line of treatment for warm AIHA. Supportive treatment including vitamin supplementation, recombinant erythropoietin, thrombosis prophylaxis and the prevention and treatment of infections is essential.
    [Show full text]
  • A Case of COVID-19-Associated Autoimmune Hemolytic Anemia with Hyperferritinemia in an Immunocompetent Host
    Open Access Case Report DOI: 10.7759/cureus.16078 A Case of COVID-19-Associated Autoimmune Hemolytic Anemia With Hyperferritinemia in an Immunocompetent Host Zoha Huda 1 , Abdullah Jahangir 2 , Syeda Sahra 3 , Muhammad Rafay Khan Niazi 3 , Shamsuddin Anwar 2 , Allison Glaser 4 , Ahmad Jahangir 5 1. Medicine, The City University of New York (CUNY) School of Medicine, New York, USA 2. Internal Medicine, Staten Island University Hospital, Northwell Health, New York, USA 3. Internal Medicine, Northwell Health, New York, USA 4. Infectious Disease, Northwell Health, New York, USA 5. Internal Medicine, Mayo Hospital, Lahore, PAK Corresponding author: Syeda Sahra, [email protected] Abstract We report an interesting case of a middle-aged gentleman who presented with diabetic ketoacidosis (DKA) and tested polymerase chain reaction (PCR) positive for COVID-19 infection. His hospital stay was complicated by acute kidney injury, hematuria, and normocytic anemia. Initial chest x-ray demonstrated bibasilar opacities. D-dimer and C-reactive protein were elevated. During his hospital stay, his hemoglobin decreased from 13.4 g/dL to 9 g/dL, and further workup demonstrated ferritin of 49,081 ng/mL with lactate dehydrogenase of 1665 U/L. He was treated with prednisone and folic acid for autoimmune hemolytic anemia (AIHA). Ferritin was downtrended, and hemoglobin stabilized. As demonstrated by this case report and prior literature review, COVID-19 infection can be associated with AIHA. Categories: Infectious Disease, Hematology Keywords: covid-19, hyperferritinemia, high ferritin, autoimmune hemolytic anemia (aiha), hemolytic anemia Introduction Information regarding COVID-19 and associated coagulopathies is rapidly evolving and expanding. Thus far, many cases of autoimmune hemolytic anemia (AIHA) have been reported in patients with comorbidities such as thrombocytopenia, leukemia, lymphoma, various cancers, and autoimmune conditions [1].
    [Show full text]
  • Acoi Board Review 2017 Text
    CHERYL KOVALSKI, DO FACOI NO DISCLOSURES ACOI BOARD REVIEW 2017 TEXT ANEMIA ‣ Hemoglobin <13 grams or ‣ Hematocrit<39% TEXT IRON DEFICIENCY ‣ Most common nutritional problem in the world ‣ Absorbed in small bowel, enhanced by gastric acid ‣ Absorption inhibited by inflammation, phytates (bran) & tannins (tea) TEXT CAUSES OF IRON DEFICIENCY ‣ Blood loss – most common etiology ‣ Decreased intake ‣ Increased utilization-EPO therapy, chronic hemolysis ‣ Malabsorption – gastrectomy, sprue ‣ ‣ ‣ TEXT CLINICAL MANIFESTATIONS OF IRON DEFICIENCY ‣ Impaired psychomotor development ‣ Fatigue, Irritability ‣ PICA ‣ Koilonychiae, Glossitis, Angular stomatitis ‣ Dysphagia TEXT ANEMIA MCV RETICULOCYTE COUNT Corrected retic ct : >2%: blood loss or hemolysis <2%: hypoproliferative process TEXT ANEMIA ‣ MICROCYTIC ‣ Obtain and interpret iron studies ‣ Serum iron ‣ Total iron binding capacity (TIBC) ‣ Transferrin saturation ‣ Ferritin-correlates with total iron stores ‣ can be nml or inc if co-existent inflammation TEXT IRON DEFICIENCY LAB FINDINGS ‣ Low serum iron, increased TIBC ‣ % sat <20 TEXT MANAGEMENT OF IRON DEFICIENCY ‣ MUST LOOK FOR SOURCE OF BLEED: ie: GI, GU, Regular blood donor ‣ Replacement: 1. Oral: Ferrous sulfate 325 mg TID until serum iron, % sat, and ferritin mid-range normal, 6-12 months 2. IV TEXT SIDEROBLASTIC ANEMIAS Diverse group of disorders of RBC production characterized by: 1. Defect involving incorporation of iron into heme molecule 2. Ringed sideroblasts in bone marrow javascript:refimgshow(1) TEXT CLASSIFICATION OF SIDEROBLASTIC
    [Show full text]
  • Acrocyanosis – a Symptom with Many Facettes
    ID Design Press, Skopje, Republic of Macedonia Open Access Macedonian Journal of Medical Sciences. 2018 Jan 25; 6(1):208-212. Special Issue: Global Dermatology-2 https://doi.org/10.3889/oamjms.2018.035 eISSN: 1857-9655 Review Article Acrocyanosis – A Symptom with Many Facettes Uwe Wollina1*, André Koch1, Dana Langner1, Gesina Hansel1, Birgit Heinig2, Torello Lotti3, Georgi Tchernev4,5 1Städtisches Klinikum Dresden - Department of Dermatology and Allergology, Dresden, Sachsen, Germany; 2Städtisches Klinikum Dresden - Center of Physical and Rehabilitative Medicine, Dresden, Germany; 3University G. Marconi of Rome - Dermatology and Venereology, Rome, Italy; 4Department of Dermatology, Venereology and Dermatologic Surgery, Medical Institute of Ministry of Interior, Sofia, Bulgaria; 5Onkoderma, Policlinic for Dermatology and Dermatologic Surgery, Sofia, Bulgaria Abstract Citation: Wollina U, Koch A, Langner D, Hansel G, Acrocyanosis is an uncommon complaint belonging to the acro-syndromes. It typically presents with coolness and Heinig B, Lotti T, Tchernev G. Acrocyanosis – A bluish discolourations of hands, feet, ears, nose, lips and nipple. The most frequently affected parts of the body Symptom with Many Facettes. Open Access Maced J Med Sci. 2018 Jan 25; 6(1):208-212. are the hands. This review discusses physical factors, vascular disorders, infectious diseases, haematological https://doi.org/10.3889/oamjms.2018.035 disorders, solid tumours genetic disorders, drugs, eating disorders, and spinal disease presenting as or leading to Keywords: Acrocyanosis; hands and feet; vascular acrocyanosis. disorders; Raynaud syndrome; Connective tissue diseases; Adverse drug reactions; Tumors *Correspondence: Uwe Wollina. Städtisches Klinikum Dresden - Department of Dermatology and Allergology, Dresden, Sachsen, Germany. E-mail: wollina- [email protected] Received: 28-Jul-2017; Revised: 27-Oct-2017; Accepted: 30-Oct-2017; Online first: 10-Jan-2018 Copyright: © 2018 Uwe Wollina, André Koch, Dana Langner, Gesina Hansel, Birgit Heinig, Torello Lotti, Georgi Tchernev.
    [Show full text]
  • Kawasaki Disease with Autoimmune Hemolytic Anemia
    CASE REPORTS Kawasaki Disease with Autoimmune Hemolytic Anemia DHWANEE THAKKAR, NITA RADHAKRISHNAN, *PK PRUTHI AND A NUPAM SACHDEVA From Pediatric Hematology Oncology and BMT Unit; and *Institute of Child Health; Sir Ganga Ram Hospital, Rajinder Nagar, New Delhi, India. Correspondence to: Background: Association of autoimmune haemolytic anaemia has been seldom reported Dr Anupam Sachdeva, with Kawasaki disease. Case characteristics: A 7-month-old boy, presented with Head of Department, prolonged fever, erythematous rash, severe pallor and hepatosplenomegaly. Institute of Child Health, Observations: Positive Direct Coombs test and coronary artery aneurysm on Sir Ganga Ram Hospital, Rajinder Nagar, echocardiography. He was managed with steroids along with intravenous immunoglobulins New Delhi 110 060, India. and aspirin. Outcome: Early identification of the condition helped in the management. [email protected] Message: Patients of autoimmune hemolytic anemia with unusual features such as Received: July 30,2014; prolonged fever, skin rash, and mixed antibody response in Coombs test should be Initial review: November 24, 2014; evaluated for underlying Kawasaki disease as a possible etiology. Accepted: January 8, 2015. Keywords: Autoimmunity, Coombs test, Coronary artery aneurysm. utoimmune haemolytic anemia (AIHA) chain reaction (PCR) for cytomegalovirus (CMV) was occurs in children either secondary to 19362 copies/mL. PCR for Ebstein-Barr virus was infections, autoimmune conditions and drugs, negative. There was no evidence of pneumonia on chest Aor may be primary [1]. Several hematological X-ray. Bone marrow examination showed erythroid abnormalities have been described in Kawasaki disease. hyperplasia. AIHA is a rare association, and most cases have occurred In view of the prolonged fever, erythematous rash and after infusion of intravenous immunoglobulins (IVIG) desquamation of extremities, he was investigated for in Kawasaki disease [2].
    [Show full text]
  • Too Few Red Blood Cells Medical Term
    Too Few Red Blood Cells Medical Term When Hadleigh vouchsafes his touters lurk not tautologically enough, is Normand condign? Trever smoodge conceivably while scrawlier Zachary amplified statically or waters obstructively. Word-blind and derogative Roderigo rewashes some corollary so hortatively! How can be successfully treated by blood cells deep in times in memory loss Solved HSCs have the potential to to long-term cures for immune-related disease. Polycythemia and Hyperviscosity in the Newborn. Thrombocytosis is the medical term used to describe the widespread of elevated. Cases particularly cases of PV can update more serious and savings long-term. Nucleated RBC Definition Ranges And Causes SightDX. The body is to decide about the body by the amount of four syndromes, red blood cells, attorney general counseling depending on. Medical Term after Part Meaning hemtaology hematblood. A useful trend of ABP but red all medical procedures it carries its own sets of. That 1463 544 met the World Health Organization definition for anemia. Hematocrit definition is the ratio of the helmet of gross blood cells to understand total volume less blood. Medical ReviewE Gregory Thompson MD Internal Medicine Adam. Anaemia is a medical term for those red blood cell color or haemoglobin and. The runway of basic research in bit is to know understand you In the. Medical problems over detect due how long-term exposure to low forehead while. How amplify is series high RBC? Bone Marrow Tests MedlinePlus Medical Test. Medical Dictionary of Health search A-C Harvard Health. Long-term hull of myeloid growth factors to spill the WBC count normal e.
    [Show full text]
  • Ask a Pathologist Jessica Kneib1, Emily Coberly1
    AJHM Volume 2 Issue 1 (Jan-March 2018) ASK A SPECIALIST ASK A SPECIALIST Ask a Pathologist Jessica Kneib1, Emily Coberly1 1Department of Pathology and Anatomical Sciences, University of Missouri Health Care, Columbia, MO Correspondence: Emily Coberly, MD. One Hospital Dr. Columbia, MO 65212 ([email protected]) Received: January 10, 2018 Accepted: February 2, 2018 Published: February 16, 2018 Am J Hosp Med 2018 Jan;2(1):2018.005 https://doi.org/10.24150/ajhm/2018.005 Question: After ordering a type and screen I was notified by the blood bank that my patient has cold autoantibodies. Does this mean that my patient has a cold agglutinin disease? Answer: Many patients have antibodies in C. Blood samples in the laboratory may their plasma which bind to antigens present spontaneously agglutinate, and the on the surface of their own red blood cells. peripheral smear shows clumps of Commonly, these autoantibodies are easily agglutinated red blood cells (Figure 1). detectable in the laboratory at cold temperatures (4° C) but may be very weak or undetectable when the samples are warmed to body temperature (37° C). While cold autoantibodies are generally not clinically significant and do not cause hemolysis in the patient, they may delay serologic testing of the blood. Autoantibodies can obscure the identification of underlying clinically significant alloantibodies, requiring additional testing to find appropriate crossmatch compatible units for transfusion. Figure 1. Peripheral smear demonstrating red blood Although the majority of cold cell agglutination due to cold agglutinin disease. autoantibodies are benign, they may rarely be associated with hemolysis. The direct antiglobulin test (DAT) is Cold agglutinin disease (CAD) is a positive for complement (C3) and negative rare type of autoimmune hemolytic anemia for IgG.
    [Show full text]